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Background: Glutathione (GSH) is one of the most important agents of the antioxidant defense system of the cell
because, in conjunction with the enzymes glutathione peroxidase (GSH-Px) and glutathione S transferase pi (GSTpi),
it plays a central role in the detoxification and biotransformation of chemotherapeutic drugs. This study evaluated
the expression of GSH and the GSH-Px and GSTpi enzymes by immunohistochemistry in 30 canine mammary
tumors, relating the clinicopathological parameters, clinical outcome and survival of the bitches. In an in vitro study,
the expression of the genes glutamate cysteine ligase (GCLC) and glutathione synthetase (GSS) that synthesize GSH
and GSH-Px gene were verified by qPCR and subjected to treatment with doxorubicin, to check the resistance of
cancer cells to chemotherapy.
Results: The immunohistochemical expression of GSH, GSH-Px and GSTpi was compared with the clinical and
pathological characteristics and the clinical outcome in the bitches, including metastasis and death.
The results showed that high immunoexpression of GSH was correlated to the absence of tumor ulceration and
was present in dogs without metastasis (P < 0.05). There was significant correlation of survival with the increase of
GSH (P < 0.05). The expression of the GSH-Px and GSTpi enzymes showed no statistically significant correlation with
the analyzed variables (p > 0.05). The analysis of the relative expression of genes responsible for the synthesis of
GSH (GCLC and GSS) and GSH-Px by quantitative PCR was done with cultured cells of 10 tumor fragments from
dogs with mammary tumors.
The culture cells showed a decrease in GCLC and GSS expression when compared with no treated cells (P < 0.05).
High GSH immunoexpression was associated with better clinical outcomes.
Conclusion: Therefore, high expression of the GSH seems to play an important role in the clinical outcome of
patients with mammary tumors and suggest its use as prognostic marker. The in vitro doxorubicin treatment
significantly reduces the expression of GCLC and GSS genes so we can consider them to be candidates for
predictive markers of therapeutic response in mammary cancer.
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Clinical and molecular characteristics of tumors may as-
sist in the development of more efficient and less toxic
therapeutic strategies. In this way, the expression of anti-
oxidant proteins in tumor cells has been investigated as
a predictor and prognostic factor in cytotoxic treatment
in breast cancer [1].
When there is an excessive production of reactive oxi-
dative species (ROS), the antioxidant defense system is
triggered, which is of great importance in the physiopa-
thology of diverse cancer types, including breast cancer
[2,3]. The consequence of this process is the loss of cellu-
lar function and progression towards cell death. Moreover,
oxidative stress leads to DNA damage and mutations in
tumor suppressor genes, events that can be important in
the initiation of carcinogenesis [4].
GSH is a tripeptide of glycine, cysteine and glutamic
acid that is found in high concentration intracellularly, be-
ing the most abundant low molecular mass thiol [5]. Syn-
thesis of GSH requires the consecutive action of two
enzymes, first glutamate-cysteine ligase (GCLC) that con-
jugates glutamic acid and cysteine forming gama-glutamyl
cysteine. This compound containing cysteine with a sulfhy-
dryl group (SH) is responsible for the antioxidant activity
of GSH. The second reaction is the binding of gama-
glutamyl cysteine with glycine by the enzyme glutathione
synthetase (GSS), giving rise to the tripeptide gama-
glutamyl cysteine glycine-glutathione [6,7].
GSH-Px is an 80 kDa protein composed of four identical
sub-units. Five isoforms of GSH-Px are well characterized
in mammals and show tissue-specific distribution. Alter-
ation of these enzyme levels are associated with diverse
cancer types, including skin, kidney, intestine and breast
cancer [8].
GSTs are a family of intracellular enzymes of detoxifi-
cation phase II that catalyze diverse electrophilic com-
pounds conjunction to GSH, blocking DNA mutations
of the cells [9].
Admittedly, the classification of mammary neoplasms
in female dogs is complex and detailed, but it cannot
predict the progress of the illness and the survivor time
of the animal with cancer nor the chemotherapeutic
and/or hormonal treatment feedback. Nowadays, using
the possibility of immunohistochemistry diagnosis of the
tumors by biomarkers, prognosis can be more accurate
and its predictable value can also direct genetic treatment.
Besides, the biomarkers that apparently do not have inde-
pendent prognostic value, together with the clinic-
pathologic parameters, may assist in the evaluation of
feedback to the patient’s clinical development.
Despite advances in identification of genes involved in
tumor growth, progression and resistance to drugs, the
way these genes interact with one another remains un-
clear. Therefore a better understanding of how molecularmarkers are associated with therapeutic response is indis-
pensable in selecting the correct drugs for treatment. The
capacity to establish primary cell cultures of tumors is an
important requirement in cancer research, allowing the
identification of important prognostic factors and thera-
peutic agents. Moreover, this is the best way of assessing
the predictive value of adjuvant treatment that might also
be given to cancer patients [10].
Primary cultures have been successfully used to get an-
swers to drug dosages and to support new anti-cancer
drug development [11]. The enzymatic system of glutathi-
one/glutathione transferases (GSH/GSTs) is seen as one of
the most important in cellular resistance to multiple drugs
(MDR), involving the alteration of GSH level, the expres-
sion of genes that codify the enzymes responsible for its
synthesis, and the genes that code for GSTs [5].
The aim of this study has been to assess the expression
of GSH and the enzymes GSTpi and GSH-Px by immu-
nohistochemistry in mammary tumors and to infer their
prognostic value. An in vitro study of molecular analyses




Bitches from the test group were evaluated with respect to
physical (age), pathological (Histological type, time course
– interval between tumor diagnosis and surgical removal,
number of nodules, clinical staging, ulceration and
vascularization) and clinical (metastasis, censure) charac-
teristics. The animals ranged from 6 to 16 years of age, the
mean at diagnosis being 10 years. With respect to the
breed, there were 12 (40%) mongrels, eight (27%) poodles,
three (10%) cockers and three (10%) boxers, two (7%)
pinchers, one (3%) basset and one (3%) dachshund. A total
of 30 canine mammary lesions (6 benign and 24 malignant
tumors) were histopathologically diagnosed, the benign
tumors being composed of three mixed benign tumors,
two sarcomatoid-like lesion and one papilloma while the
malignant tumors included 14 carcinomas in mixed tu-
mors, three papillary carcinomas, two carcinosarcomas,
two tubulopapillary carcinomas, one comedocarcinoma,
one solid carcinoma and one inflammatory carcinoma.
There was a predominance of clinical staging I (37%).
Among the clinicopathological characteristics, 21 (70%) of
the tumors had multiple numbers of nodules, 18 (60%) tu-
mors had the absence of ulceration and 15 (50%) had
moderate vascularization. The metastasis and death index
was 27% where all the cases of death occurred from pul-
monary metastasis. All the data were described in Table 1.
Immunohistochemistry study
Immunostaining of GSH was evident in the cytoplasm
of neoplastic cells, and GSTpi and GSH-Px were also
Table 1 Correlation between the three antibody stains with the clinic and pathologic factors of the female dogs
Clinical and pathologic factors Number of bitches GSH GSTpi GSH-Px
Age
≥ 10 years 16 (53.3%) 185.3 ± 6.532 202.8 ± 2.537 194.4 ± 3.838
< 10 years 14 (46.7%) 196.9 ± 6.170 206.5 ± 1.842 202.3 ± 2.936
P > 0.05 > 0.05 > 0.05
Time course
Until 6 months 13 (50%) 196.5 ± 21.82 204.6 ± 6.172 202.9 ± 13.81
Between 6 and 18 months 7 (27%) 182.3 ± 31.20 205.5 ± 9.397 192.5 ± 13.55
More than 18 months 6 (23%) 180.0 ± 24.07 202.5 ± 14.49 190.8 ± 14.18
P > 0.05# > 0.05# > 0.05#
Histological type
Malignant tumors 26 (87%) 189.9 ± 4.829 204.0 ± 1.757 198.3 ± 2.869
Benign 4 (13%) 196.3 ± 15.69 209.3 ± 3.860 203.5 ± 4.173
P > 0.05 > 0.05 > 0.05
Clinical staging
I 11 (37%) 202.3 ± 15.36 204.7 ± 5.746 199.4 ± 11.83
II 4 (13%) 190.0 ± 45.03 208.0 ± 4.243 198.3 ± 19.57
III 10 (33%) 183.3 ± 24.50 202.2 ±12.75 196.4 ± 13.09
IV 5 (17%) 180.6 ± 21.13 206.0 ± 8.689 198.4 ± 18.94
P > 0.05# > 0.05# > 0.05#
Number of nodules
Multiples 9 (30%) 177.9 ± 7.181 204.6 ± 2.844 200.8 ± 5.112
Single 21 (70%) 196.2 ± 5.314 204.5 ± 2.001 197.4 ± 3.044
P > 0.05 > 0.05 > 0.05
Tumor ulcerated
Ulceration 10 (34%) 180.8 ± 22.75 203.5 ± 13.53 205.0 ± 9.129
Necrosis 2 (7%) 162.0 ± 55.15 204.9 ± 5.557 189.5 ± 6.364
Absent 17 (59%) 199.4 ± 19.52 206.0 ± 8.485 195.2 ± 15.34
P 0.03* # > 0.05# > 0.05#
Tumor vascularization
Abundant 15 (50%) 184.1 ± 7.164 205.7 ± 2.080 197.9 ± 3.349
Moderate 15 (50%) 197.3 ± 5.374 203.3 ± 2.499 198.2 ± 3.914
P > 0.05 > 0.05 > 0.05
Censure
Death 8 (26.7%) 165.5 ± 8.592 204.1 ± 1.869 203.0 ± 3.937
Living 22 (73,3%) 199.9 ± 3.921 205.9 ± 1.191 196.3 ± 3.099
P 0.0003* > 0.05 > 0.05
Metastasis
Yes 8 (26.7%) 165.5 ± 8.592 204.1 ± 1.869 203.0 ± 3.937
No 22 (73.3%) 199.9 ± 3.921 205.9 ± 1.191 196.3 ± 3.099
P 0.0003* > 0.05 > 0.05
*Significant value to Student’s t test # ANOVA test.
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stroma (Figure 1).
There was no correlation between the expression of
the GSH and clinical characteristics and pathology with
the age, time course, histological type, clinical staging,
number of nodules and tumor vascularization (P > 0.05;
Table 1). However, the high expression of GSH had sta-
tistically significant correlation in female dogs with non-
ulcerated tumors (P = 0.03; Table 1).
The expression of GSH, GSTpi and GSH-Px by immu-
nohistochemistry was compared with the clinical develop-
ment of the female dogs, including metastasis and death.
The metastasis index was 26.7% and the same for the
death index (Table 1). GSH expression increased in female
dogs that survived to the end of follow-up (P = 0.0003;
Table 1) and it also increased in those female dogs that
did not present metastasis (P = 0.0003; Table 1). ThereFigure 1 Photomicrograph of the immunohistochemistry procedure d
tumors. AXIOSKOP2, 40X. A. GSH Immunostaining (medium intensity). B. GSH
D. GSH-Px Immunostaining (low intensity). E. GSTpi Immunostaining (high intwas no significant statistical relation between the analyzed
variables and the expression of the enzymes GSTpi and
GSH-Px (P > 0.05; Table 1).
To generate the ROC curve, the values of the GSH,
GSTpi and GSH-Px expression of the female dogs that
died were compared to those that survived. The ROC
curves indicate the performance and the limit values for
GSH, GSTpi and GSH-Px expression in predicting the
risk of mortality, and calculated the sensitivity/specifi-
city, thereby establishing the best cut-off to discriminate
high-death-risk dogs, which for GSH expression was: M.D.
O. = 197 u.a. (sensitivity = 100% and specificity = 70%),
GSTpi expression was: M.D.O. = 212 u.a. (sensitivity = 43%
and specificity = 88%) and GSH-Px expression: M.D.O. 197
u.a. (sensitivity = 71% and specificity = 59%).
The dogs were followed-up from 1–18 months for over-
all survival, with a median of 540 days. The relationshipemonstrating antibody staining in female dogs with mammary
Immunostaining (negative). C. GSH-Px Immunostaining (high intensity).
ensity). F. GSTpi Immunostaining (medium intensity).
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and survival of patients was evaluated by Kaplan–Meier
analysis and log-rank test, using the cut-off value estab-
lished by the ROC curve.
We found that the overall survival of patients with low
GSH expression was significantly shorter than patients
with high GSH expression (P = 0.002; Figure 2). The me-
dian survival time of dogs that died was 6.5 months. There
was no correlation between GSTpi and GSH-Px expres-
sion and overall survival (P > 0.05; data not shown).
In vitro study
10 tumor specimens were used from the 30 samples used
for immunohistochemistry, which were histopathologically
identified as seven carcinomas in mixed tumors, two tubu-
lopapillary carcinomas and one papillary carcinoma. After
treatment with doxorubicin, all the samples showed under-
expression of the GSH gene compared with the control
group (without treatment) (P = 0.0001; Figure 3) and the
GSS gene was also expressed more weakly in the presence
of the drug in 90% of the samples (P = 0.001) (Figure 4).
There was no significant statistical difference between
GSH-Px gene expression in the control group relative to
the group treated with doxorubicin (P > 0.05; Figure 5).
Discussion
In this study, there was an increase in GSH expression in
tumors without ulceration, not metastatic tumors and low
mortality. Our results are in agreement with Buser et al.
[12] who demonstrated that high levels of GSH, GSTpi
and GSH-Px were associated with favorable clinical char-
acteristics and good prognosis, whereas low levels of GSH
and GST activity were associated with more aggressive or
more advanced disease.
After 18 months, no significant results were observed
when comparing the GSTpi and GSH-Px expression
with metastasis and death in our dogs. Our results areFigure 2 Survival rates for female dogs according to GSH
expression. Overall survival for high GSH expression (dotted line)
versus low GSH expression (continuous line) (selected cut-off = M.O.
D. = 197 a.u.) (p = 0.002 / OR. 0.07 / C.I. 95%: 0.02 to 0.43). OR = odds
ratio; C.I. = confidence interval.in agreement with Jardim et al. [1] where no statistical
correlation was found between GSTpi expression and
local recurrence and/or metastasis either.
In this study, we verified the influence of chemotherapy
with doxorubicin on the GSH and GSH-Px genes expres-
sion. According to cell culture growing curves, doxorubi-
cin efficiently causes tumor cell death.
Moreover, doxorubicin treatment reduces the expres-
sion of the genes GCLC and GSS, respectively, in treated
tumor cells over untreated tumor cells. GCLC sensitizes
the enzyme glutamate cysteine ligase to catalyze the first
step for GSH synthesis and GSS codes for glutathione
synthetase catalyzing the second and last step of synthesis
of GSH. Together, these data support the notion that doxo-
rubicin reduces a pattern of gene expression associated with
modulation of the antioxidant capacity of mammary tumor
cells.
Many studies have shown alterations in GSH activity after
in vitro treatment with doxorubicin or similar drugs. Our
results agree with Ozkan and Fiskin [13], in which epiru-
bicin - a structural analog of doxorubicin - decreases GSH
activity after 24 h in cultured mammary neoplastic cells.
Some studies suggest that reactive oxygen species (ROS)
production in doxorubicin treatment is responsible for
cytotoxicity in neoplastic cells, which could induce the
synthesis of antioxidant enzymes, such as GSH and GSH-
Px, making the neoplastic cells resistant to oxidative dam-
age [14]. In the same way, Han et al. [15] found greater
sensitivity to doxorubicin when the GSH levels decreased
in the mammary carcinoma cell line (MCF-7). However,
in contrast, Di et al. [16] demonstrated that GSH overex-
pression did not prevent tumor cell apoptosis after treat-
ment with doxorubicin, suggesting that the cytotoxicity of
the drug might not be wholly related to ROS production.
Additionally, the involvement of GSH in the therapeutic
response to doxorubicin is controversial. Some authors
suggest that GSH inhibition leads to the drug accumulat-
ing in the nucleus of the tumor cells [17,18], whereas
others suggest that resistance to doxorubicin and other
similar drugs is not directly related to the binding of the
drug to GSH [14].
Exactly what intracellular alterations are responsible for
the MDR phenotype in neoplastic cells remain largely un-
known. There is a suggestion that high concentrations of
GSH, GSH-Px and GSTpi, independent of other intracellu-
lar alterations, do not decisively contribute to MDR [19,20].
The resistance to the antineoplastic agent cisplatin, for in-
stance, has been associated to the high expression of the
enzyme gama glutamyl transpeptidase (GGT) localized at
the cell membrane, which is responsible for its degradation.
Thereby, despite the fact that cytotoxic treatment decreases
intracellular GSH concentration, this enzyme hydrolyzes
serum GSH, releasing the necessary amino acids for
intracellular GSH replenishment [21]. The enzyme GGT
Figure 3 Quantitative gene expression of GCLC, a synthesizer of GSH, in mammary tumor cells of female dogs after treatment with
doxorubicin. The treated group (white bars) showed underexpression of GCLC gene compared with the control group [untreated samples
(gray bars)] (p = 0.0001). Value of gene expression in log3.
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ance to drugs due to high levels of this enzyme has been
found in many cancer types including some mammary tu-
mors [21].
In this context, there are many studies trying to iden-
tify agents that can increase the efficiency of conven-
tional drugs and/or reverse the MDR phenotype in
neoplastic cells [22,23]. Despite the correlation between
high expression of these genes and the MDR, some
studies suggest that using agents that increase GSH,
GSH-Px and GSTs levels during drug treatment is a
promising way to reduce oxidative stress, thus reducing
the collateral effects of chemotherapy in breast cancer
patients [24-26].Figure 4 Quantitative gene expression of GSS, a synthesizer of GSH, i
doxorubicin. The treated group (white bars) showed underexpression of G
(gray bars)] (p = 0.001). Value of gene expression in log3.The mammary tumors cultivated in vitro showed under-
expression of the GSH coding genes and no alteration to
the expression of GSH-Px, after treatment with doxorubi-
cin. This can be explained by the interaction between
these two enzymes in the antioxidant defense of tumor
cells. GSH-Px has selenium at its catalytic site and uses
GSH as an electron donor for the reduction of H2O2 to
H2O [12,27]. So the results show that GSH and GSH-Px
don’t provide adequate defense against oxidants, render-
ing them sensitive to drugs.
In this context, it is necessary to clarify the mechanism
of these enzymes in cell resistance and their true prognostic
value [28,29]. Knowledge of GSH expression and its en-
zymes in a wide range of biology processes is expanding.n mammary tumor cells of female dogs after treatment with
SS gene compared with the control group [untreated samples
Figure 5 Quantitative gene expression of GSH-Px in mammary tumor cells of female dogs after treatment with doxorubicin. The
treated group (white bars) compared with the control group [untreated samples (gray bars)] showed no significant difference in the GSH-Px
expression. Value of gene expression in log3.
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will present many opportunities for the development of
therapeutic interventions in cancer and other diseases re-
lated to levels of oxidative stress [5].
Conclusion
High expression of GSH in neoplastic mammary cells
from female dogs is associated with the best clinical out-
come, including a greater survival time. Therefore this
high expression plays an important role in the clinical
outcome of patients with mammary tumors and can be
used as prognostic marker for mammary neoplasms in
female dogs.
Treatment of mammary neoplastic cells with doxo-
rubicin in vitro is an efficient way to induce cell death,
reducing the expression of the GCLC and GSS genes
that are related to antioxidant production. Thus they
can be considered potential predictive markers on the
therapeutic feedback to breast cancer. More studies,
using large cohorts in future studies, are needed to con-
firm the prognostic value of these markers in the mam-




Tumor fragments were collected from 30 female dogs
with mammary neoplasia that were brought to the veter-
inary clinics (São José do Rio Preto and region) during
the years of 2009 and 2010. After tumor excision, the
animals were followed-up from 1–18 months, with a
median of 540 days. During follow-up time, the vets
evaluated tumor metastasis and recurrence, as well as
the cause of death of the animal.For histopathologic diagnostics, the tumor biopsies
collected were classified according to Misdorp et al. [30]
by the AFIP (Armed Forces Institute of Pathology). The
parameters employed for the classification of clinical
tumor staging were in accordance with the TNM system
(size, lymph node involvement, metastasis) established by
WHO for canine mammary gland tumors modified [31],
which recommended tumor mass size (T) – T1: < 3 cm -
T2: between 3 and 5 cm - T3: > 5 cm; lymph node in-
volvement (N) - N0: no apparent involvement - N1: uni-
lateral involvement - N2: bilateral involvement; and
distant metastasis (M) - M0: no evident metastasis - M1:
distant metastasis including non-regional lymph nodes.
Clinical staging was assigned as I, II, III or IV according to
the tumor extension and established prognosis.
The presence of local tumor recurrence, metastasis and
death were described and the overall survival was deter-
mined from the date of diagnosis until last follow-up or
death. The cause of death was evaluated by the attending
veterinarian and only female dogs that died of the illness
were included in the group for the study. The dogs that
had died of respiratory failure were diagnosed with lung
metastasis as shown by X-ray. This study was approved by
the Ethical Committee of the Faculdade de Medicina de
São José do Rio Preto (Protocol number 3945/2009).
Immunohistochemistry technique
For immunochemistry, tumor samples were embedded into
paraffin blocks and cut to give 3 μm sections. The samples
were prepared on silanized glass slides before the paraffin
was removed, the sections rehydrated in an ascending
range of alcohol concentrations and incubated with 3%
hydrogen peroxide for 30 min to block endogenous per-
oxidase activities. Antigenic recovery was made in a
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antibody. The GSH primary antibody was diluted in the
proportion of 1:100, GSTpi 1:4000 and GSH-Px 1:1200
in bovine serum albumin solution (BSA). After cooling,
the slides were covered with BSA for 30 min and incu-
bated at 4°C overnight with the antibodies.
After they had been washed with phosphate buffer (PBS)
for 15 min and incubated with Easy Path kit (Erviegas,
São Paulo, Brazil), composed of the secondary antibody
“anti-mouse, rabbit and goat immunoglobulin with Biotin”
for one h and “streptoavidin complex with peroxidase” for
30 min, followed by washes with PBS for 15 min, 0.5% of
3,3′-diaminobenzidin-tetra-hydrochloride (DAB, Signet®
Laboratories, Dedham, MA, USA) was applied to the slides
for 2–5 min at 20-22°C. The slides were counterstained
with Harris hematoxilin for 40 min. Negative controls
were obtained by the omission of the primary antibody,
and one sample of prostate was used as an internal con-
trol in each assay.
Immunohistochemistry quantification
The slides were photographed and the proteins quanti-
fied by the AxioVision software at 40× magnification
under an AXIOSKOP2 Zeiss microscope. For each
sample, three regions of the tumor tissue were selected
and 20 points of the tumor cells were marked in each
region. In this way, 60 different points were analyzed
in each sample to obtain an average relative intensity
of immunoreactivity. The values were given in arbi-
trary units (a.u.) and the mean optical density (M.O.D.)




The in vitro study was performed with tumor biopsies of
10 dogs out of the 30 with mammary tumors from the
immunohistochemistry study. The tumor biopsies were
sliced into microfragments and incubated at 37°C in 5%
CO2 in RPMI1640 (Cultilab) supplemented with 20%
BSA, 1% penicillin/streptomycin and 1% L-glutamine.
The cells were cultured until there was 80% confluence
and then immunocytochemistry was carried out with the
primary antibodies anti-cytokeratin, anti-vimentin and
anti-calponin for epithelial origin confirmation.
In vitro cell treatment
The cells from each tumor biopsy were divided into two
groups: control (untreated) and that treated with 0.2 mg
of the drug (doxorubicin, Adriamycin) for 24 h. At the
end of the treatment, cell viability was verified by cell
counting with the Neubauer chamber after staining with
trypan blue dye. The cells were submitted to immuno-
cytochemistry for confirmation of the epithelium origin,with anti- cytokeratin antibody, resulting in a positive
protein staining.
Quantitative RT-PCR (qPCR)
Total RNA was extracted from the cell cultures with
TRIZOL reagent (Invitrogen). Each sample of total RNA
was subjected to reverse transcription using a High Cap-
acity cDNA kit (Applied Biosystems).
The quantitative PCR (qPCR) was performed accord-
ing to Bustin et al. [32].
The polymerase chain reaction (qPCR) was made in
triplicate using the equipment Step One Plus (Applied
Biosystems). The reaction had a final volume of 20 μL,
with 10 μL of Power SYBR Green PCR Master Mix (Ap-
plied Biosystems), 250 μL of each primer, and 10 ng of
cDNA. The qPCR conditions were 50°C for 2 min, 95°C
for 10 min, followed by 35 cycles of 95°C for 15 s and
60°C for 1 min. The dissociation curve was analyzed to
confirm the desired genetic product: one cycle of 95°C
for 15 s, 60°C for 1 min, and 95°C for 15 s.
Endogenous control of the genes RPS19 and RPL8
were used for normalization. The transcription level was
calculated by the 2-ΔCt method [33]. The Ct number
(relative abundance) was calculated using the 2-ΔΔCT
formula and was plotted as mean ± SD of the triplicates
reaction.
The genes were selected from PUBMED. The GCLC
and GSS genes were selected because they synthesize
GSH, and the gene GST-Pi was not used in this study
because its sequence was not available for the canine
specie. Primers were designed with PRIMER3 software.
The primers used for amplification were: GCLC sense
(5′-CCAAGTCCCTCTTCTTTCCTG-3′) and antisense
(5′-CGGAGACGGTGT ATTCTTGTC-3′) [GenBank: N
G_012071.1]; GSS sense (5′-AGCCAATGCTCTGGTGC
TAC-3′) and antisense (5′-ACCTTCGACGGATTACA
TGG-3′) [GenBank: NG_008848.1]; GSH-Px sense (5′-
GGCATCAGGAAAACGCTA AG-3′) and antisense (5′-
CCTCGCACTTCTCAAAAAGC-3′) [GenBank: NG_012
264.1]; RPS19 (internal control), sense (5′-CCTTCCT
CAAAAAGTCTGGG-3′) and antisense (5′-GTTCTCA
TCGTAGGGAGCAAG-3′) [GenBank: NG_007080.2];
and RPL8 (internal control), sense (5′- CCATGAATC
CTGTGGAGC-3′) and antisense (5′-GTAGAGGGTTT
GCCGATG-3′) [GenBank: NC_000008.10]. They were
classified as subexpressed [samples with values lower
than −1 (Log3)] and superexpressed [samples that pre-
sented values higher than −1 (Log3)].
Statistical analyses
All the analyses were done with the assistance the Graph-
Pad Prism4 and StatsDirect software. The female dogs were
grouped according to their clinical-pathological variables:
age, time course, histological type, clinical staging, number
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metastasis and death. The average referred to the densi-
tometry, and quantification for the different mammary
tumor groups was compared with Student’s t test or
ANOVA, followed by Bonferroni test. The values were
expressed as mean ± S.E.M.
The cutoff for the death risk was determined by the
ROC curve. This analysis graphically represents the com-
parison between the sensitivity distribution specifically for
each factor, or the true positive index or the false positive
index. Whenever the ROC curve is closer to the left su-
perior quadrant, the test variable is more precise, since the
positive value (sensitivity) would be closer to 1 and false
positive (specificity) closer to 0 [34]. Survival curves were
plotted using the Kaplan-Meier method and the differ-
ences between the curves were evaluated by a log-rank
test and hazard function. All the 30 female dogs of the
study were included in this analysis, and each death case
is represented by the decrease of the survival percent in
the graph in the correspondent day of the death. The
overall survival was determined from the date of diagnosis
until last follow-up or death.
To determine the possible association between the rela-
tive differences of the genetic expression of the groups, the
Man-Whitney U test was used. P < 0.05 was adopted as
significant.
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OR: Odds ratio; PBS: Phosphate buffer solution; PCR: Polimerase chain
reaction; qPCR: Quantitative real time PCR; ROC: Receiver operating
characteristcs; ROS: Reactive oxygen species; RPL8: Ribosomal protein L8;
RPS19: Ribosomal protein S19; S.E.M.: Standard deviation; SH: Sulfhydryl
group; TNM: Clinical staging system: T = tumor, N = node, M =metastasis;
a.u.: Arbitrary units.
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